Aspirin-exacerbated respiratory disease

Pham, Duy Le; Lee, Ji-Ho; Park, Hae‐Sim

doi:10.1097/mcp.0000000000000328

Cited by 22 publications

(17 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AERD is a major clinical phenotype of nonsteroidal anti-inflammatory drugs (NSAIDs) hypersensitivity that affects 0.3-2.5% of the general population [102] and 7.2% of patients with asthma [103]. It includes asthma and CRS with nasal polyposis, with exacerbated symptoms upon ingestion of cyclooxygenase (COX)-1 inhibitors (aspirin and nonselective NSAIDs).…”

Section: Aspirin-exacerbated Respiratory Diseasementioning

confidence: 99%

“…It includes asthma and CRS with nasal polyposis, with exacerbated symptoms upon ingestion of cyclooxygenase (COX)-1 inhibitors (aspirin and nonselective NSAIDs). Patients with AERD have a higher prevalence of severe asthma (14.9%) and a need for high-dose corticosteroids compared to aspirin-tolerant asthma [9,103]. 7% of the asthmatics are aspirin sensitive and the prevalence doubles in severe asthmatics.…”

Section: Aspirin-exacerbated Respiratory Diseasementioning

confidence: 99%

“…In a case-control study, YELKEN et al [154] found a significantly higher prevalence of VCD in asthmatic adults (19%) versus controls (5%; p<0.001). The prevalence of VCD is up to 40% in patients with difficult-to-control asthma [136] and is associated with a poorer quality of life [103], but little is known about the true prevalence of VCD in severe asthma because most studies have examined selected patient groups [46]. VCD is often misdiagnosed as asthma, which leads to an inappropriate choice of treatment options for subjects with this condition and inappropriate stepping up of medications to generate a better therapeutic response for "unresponsive" asthma, which places the patient at risk for more potential adverse effects and greater medical costs [12,155].…”

Section: Vcd and Asthmamentioning

confidence: 99%

“…The treatment of VCD includes nonpharmacological and pharmacological therapies [103]. Laryngeal control therapy with a speech pathologist is the cornerstone of VCD treatment [146,155,157].…”

Section: Vcd and Asthmamentioning

confidence: 99%

See 3 more Smart Citations

Current opinions for the management of asthma associated with ear, nose and throat comorbidities

Tiotiu

Plavec

Novakova³

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

Ear, nose and throat (ENT) comorbidities are common in patients with asthma and are frequently associated with poorer asthma outcomes. All these comorbidities are “treatable traits” in asthma. Identification and management of these disorders may spare medication usage and contribute to improved asthma control and quality of life, and a decrease in exacerbation rates.This review summarises recent data about the prevalence, clinical impact and treatment effects of ENT comorbidities in asthma including allergic rhinitis, chronic rhinosinusitis with and without nasal polyposis, aspirin-exacerbated respiratory disease, obstructive sleep apnoea and vocal cord dysfunction.Many of these comorbidities are possible to be managed by the pulmonologist, but the collaboration with the ENT specialist is essential for patients with chronic rhinosinusitis or vocal cord dysfunction. Further rigorous research is needed to study the efficacy of comorbidity treatment to improve asthma outcomes, in particular with the development of biotherapies in severe asthma that can also be beneficial in some ENT diseases.

show abstract

Section: Aspirin-exacerbated Respiratory Diseasementioning

confidence: 99%

Section: Aspirin-exacerbated Respiratory Diseasementioning

confidence: 99%

Section: Vcd and Asthmamentioning

confidence: 99%

Section: Vcd and Asthmamentioning

confidence: 99%

See 2 more Smart Citations

Current opinions for the management of asthma associated with ear, nose and throat comorbidities

Tiotiu

Plavec

Novakova³

et al. 2018

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…Oral aspirin challenge is considered the gold standard diagnostic method; however, its use is often limited by the risk of severe reactions during the test. The bronchial aspirin challenge is safer and consumes less time; however, it is limited by its low sensitivity [ 11 ]. In addition, oral or bronchial aspirin challenge test has limitations that cannot be used to predict the treatment or prognosis of NERD.…”

Section: Introductionmentioning

confidence: 99%

Potential Biomarkers for NSAID-Exacerbated Respiratory Disease

Park

Choi

Jung

et al. 2017

Mediators of Inflammation

Self Cite

View full text Add to dashboard Cite

Asthma is a common chronic disease with several variant phenotypes and endotypes. NSAID-exacerbated respiratory disease (NERD) is one such endotype characterized by asthma, chronic rhinosinusitis (CRS) with nasal polyps, and hypersensitivity to aspirin/cyclooxygenase-1 inhibitors. NERD is more associated with severe asthma than other asthma phenotypes. Regarding diagnosis, aspirin challenge tests via the oral or bronchial route are a standard diagnostic method; reliable in vitro diagnostic tests are not available. Recent studies have reported various biomarkers of phenotype, diagnosis, and prognosis. In this review, we summarized the known potential biomarkers of NERD that are distinct from those of aspirin-tolerant asthma. We also provided an overview of the different NERD subgroups.

show abstract

Antiviral Drugs Against Influenza Virus

Planz¹

2021

New Drug Development for Known and Emerging Viruses

View full text Add to dashboard Cite

Aspirin-exacerbated respiratory disease

Cited by 22 publications

References 82 publications

Current opinions for the management of asthma associated with ear, nose and throat comorbidities

Current opinions for the management of asthma associated with ear, nose and throat comorbidities

Potential Biomarkers for NSAID-Exacerbated Respiratory Disease

Antiviral Drugs Against Influenza Virus

Contact Info

Product

Resources

About